Gabrielle Sulzberger, an insider at Eli Lilly and Co (LLY), purchased 2,948 shares on November 16, 2025, at a price of $1,021.70 per share, totaling approximately $3.01 million. Following this transaction, Sulzberger holds 2,948 shares of the company.
Eli Lilly, headquartered in Indianapolis, Indiana, engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company operates within the pharmaceuticals industry and employs 47,000 full-time staff. Its diverse product portfolio includes treatments for cardiometabolic health, oncology, immunology, and neuroscience, with notable products such as Humalog, Jardiance, and Trulicity.
The move underscores insider confidence in the company’s prospects. However, investors should consider that insider transactions can stem from various personal or regulatory reasons. Thus, these transactions should not solely influence investment decisions.
Insider transactions are reported to the SEC, providing transparency about executives' views on their stock. Investors are encouraged to examine broader patterns of insider activity across multiple insiders and time periods for a more comprehensive understanding.